[PDF] Top 20 A phase II dose-ranging study of mirabegron in patients with overactive bladder
Has 10000 "A phase II dose-ranging study of mirabegron in patients with overactive bladder" found on our website. Below are the top 20 most common "A phase II dose-ranging study of mirabegron in patients with overactive bladder".
A phase II dose-ranging study of mirabegron in patients with overactive bladder
... (mirabegron dose) and country as fixed ...all mirabegron doses and for placebo, was evaluated using a two-sided test with a ...each mirabegron group and placebo were performed; p values and 95 ... See full document
12
Review Article Efficacy and safety of combinations of mirabegron and solifenacin in patients with overactive bladder: a systematic review and meta-analysis
... and mirabegron com- bination in comparison to solifenacin monotherapy along with investigating the safety and tolerability of this com- ...and mirabegron in overactive bladder ...of ... See full document
11
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)
... 19 patients (combination n=8, ...three patients were female with QTcF readings that ranged from 447 mseconds to 476 ...three patients (combination, n=2 ... See full document
15
Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial
... of patients, post hoc analysis of this group was not ...long patients used prior antimuscarinic therapy; as there were no re- strictions on how many antimuscarinic drugs patients had used prior to ... See full document
9
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
... double-blind, phase IV study (NCT02138747) of treatment-naïve adults with OAB ≥ 3 months randomized to 1 of 4 treatment sequences (M/T; T/M; M/M; T/T), separated by a 2-week ...and mirabegron was ... See full document
12
Onset of action of the beta 3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
... eligibility, patients were randomized if, during a 3-day micturition diary per- iod, they recorded C8 micturitions/24 h and C3 urgency episodes (based on urgency grade 3 or 4 using Patient Perception of Intensity ... See full document
8
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
... SYNERGY study was large and adequately powered, and was also clinically relevant (comprising only wet patients; a more severe group), but was otherwise very comparable with populations of previous ... See full document
31
Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice
... of mirabegron (approved in Europe in January 2013) and to allow at least 12-mo patient follow-up before analysis of the ...were mirabegron, darifenacin, fesoterodine, flavoxate, oxybutynin ER or ... See full document
11
A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
... the study were the large sample size of ap- proximately 1800 patients with OAB, and the collection of real-world data from a representative sample of patients treated in routine clinical practice in ... See full document
10
The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study
... in bladder diaries. Their study also validated improved sexual ...prospective study using the FSFI questionnaire, demonstrated that OAB symp- tom management using solifenacin had a positive out- come ... See full document
8
Mirabegron – a selective ß3-adrenoreceptor agonist for the treatment of overactive bladder
... Abstract: Overactive bladder is a common condition that significantly impacts overall quality of ...many patients fail to adhere to therapy due to troublesome side ...effects. Mirabegron is a ... See full document
5
Mirabegron as adjuvant treatment for patients with interstitial cystitis/bladder pain syndrome
... including overactive bladder (OAB), which is characterized by urinary urgency, with or without urge urinary incontinence, usually with frequency and nocturia but no ...4 Patients diagnosed with ... See full document
11
Cost effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada
... SCORPIO study), each of which had five levels of severity (Table ...status, patients could remain on current treatment, discontinue treatment, or restart previous ...of patients by severity level at ... See full document
8
<p>Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient</p>
... and mirabegron 50mg was superior to solifenacin 5mg in terms of incontinence reduc- tion, with a mean-adjusted difference of − ...and mirabegron 50mg ...of patients with zero UI episodes and those ... See full document
7
Profile of mirabegron in the treatment of overactive bladder: place in therapy
... anticholinergics. Mirabegron 50 mg caused dry mouth with an incidence simi- lar to placebo and significantly lower than ...However, patients who use mirabegron could suffer from side effects such as ... See full document
5
Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: a prospective comparative study
... OAB patients treated by antimuscarinics ranges between 65% and ...present study demonstrated constipation and dry mouth in 20 (12%) and ...urinary bladder but there may also be minimal activation in ... See full document
5
The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
... prospective study performed in two Italian ...12394/18). Patients gave their informed writ- ten consent to the ...[10]: patients having urinary symptoms of urgency with or without UUI, with fre- ... See full document
5
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
... controlled Phase III trial (n = 557) of onabotulinumtoxinA in patients with ...included, patients had to have at least three urge urinary incontinence episodes in three days and at least eight ... See full document
10
Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
... and patients were then randomized to one of eight treatment sequences of placebo crossover with once-daily (10 days) 50 mg, 100 mg, or 200 mg mirabegron or a single 400 mg moxifloxacin dose on day ... See full document
11
<p>Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential</p>
... in phase I and II trials, while bimekizu- mab entered the phase III ...the dose-ranging Phase II trial, BE ABLE, testing bime- kizumab in plaque psoriasis patients ... See full document
7
Related subjects